RosarioPW, XavierAC, CalsolariMR. 2011. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid, 21:49–53.
2.
VaismanA, OrlovS, YipJ, HuC, LimT, DowarM, FreemanJL, WalfishPG. 2010. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck, 32:689–698.
3.
NascimentoC, BorgetI, Al GhuzlanA, DeandreisD, ChamiL, TravagliJP, HartlD, LumbrosoJ, ChougnetC, LacroixL, BaudinE, SchlumbergerM, LeboulleuxS. 2011. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer, 18:R29–R40.
4.
BonnetS, HartlD, LeboulleuxS, BaudinE, LumbrosoJD, Al GhuzlanA, ChamiL, SchlumbergerM, TravagliJP. 2009. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab, 94:1162–1167.
